Therapeutic Strategies in Patients Suffering from Myocardiopathy (Awaiting Transplantation)

  • E. A. Bocchi
  • F. Bacal
  • J. O. Auler
Conference paper


The Registry of the International Society for Heart and Lung Transplantation has shown that neither the donor supply nor the post transplantation survival have changed during the last 6 years [1]. Selection of patients for heart transplantation, which maximizes the survival benefit with respect to medical therapy result, is the main way to increase the impact of this procedure for treatment of heart failure. The mortality rate for patients awaiting cardiac transplantation, on optimal medical therapy, would be 25% to 50% at 1 year, 50% to 75% at 3 years, and 90% at 5 years [2]. Accordingly, patients waiting for heart transplantation are under high risk and should receive the maximal optimized treatment for heart failure. The therapeutic approach to heart failure is directed not just towards the relief of symptoms, but to avoid progression of heart failure or death. The therapeutic approaches to heart failure are multiple and include general measures, pharmacological therapy, the use of mechanical devices as well as alternative surgical interventions [3]. Adverse effects and interaction may preclude the use of some forms in some patients. Deterioration can require modification of the therapeutic approach. Treatment must be tailored according to the needs of each patient. Each month, 4.7% of the patients listed for heart transplantation as Status II (not requiring pharmacological or mechanical support), deteriorate to the point of requiring an upgrade in their priority status, and two thirds of patients who were Status I (requiring pharmacological or mechanical support) at the time of heart transplantation were Status II at the time they were listed [4].


Chronic Heart Failure Heart Transplantation Implantable Cardioverter Defibrillator Cardiac Transplantation Severe Heart Failure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hosenpud JD, Novick RJ, Bennett LE et al (1996) The Registry of the International Society for Heart and Lung Transplantation: Thirteenth Official Report-1996. J Heart Lung Transplant 15: 655–674PubMedGoogle Scholar
  2. 2.
    Miller LW, Kubo SH, Young JB et al (1995) Report of the consensus conference on candidate selection for heart transplantation 1993. J Heart Lung Transplant 14: 562–571PubMedGoogle Scholar
  3. 3.
    The Task Force of the Working Group on Heart Failure of The European Society of Cardiology (1997) The treatment of heart failure. Eur Heart J 18: 736–753CrossRefGoogle Scholar
  4. 4.
    Stevenson LW, Warner SL, Hamilton MA et al (1992) Modeling distribution of donor hearts to maximize early candidate survival. Circulation 86 [Suppl II]: II224–II30PubMedGoogle Scholar
  5. 5.
    Haywood GA, Rickenbacher PR, Trindade PT et al (1996) Analysis of deaths in patients awaiting heart transplantation: impact on patient selection criteria. Heart 75: 455–462PubMedCrossRefGoogle Scholar
  6. 6.
    Chen JM, Weinberg AD, Rose EA et al (1996) Multivariate analysis of factors affecting waiting time to heart transplantation. Ann Thorac Surg 61: 570–575PubMedCrossRefGoogle Scholar
  7. 7.
    Stevenson LW (1996) Selection and management of candidates for heart transplantation. Curr Opinion Cardiol 11: 166–173CrossRefGoogle Scholar
  8. 8.
    Dormans TPJ, Gerlag PGG (1996) Combination of high-dose furosemide and hydrochlorothiazide in the treatment of refractory congestive heart failure. Eur Heart J 17: 1867–1874PubMedCrossRefGoogle Scholar
  9. 9.
    Packer M, Bristow MR, Cohn JN et al for the US Carvedilol Heart failure Study Group (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334: 1349–1355PubMedCrossRefGoogle Scholar
  10. 10.
    Australia/New Zealand Heart Failure Research Collaborative Group (1997) Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet 349: 375–380CrossRefGoogle Scholar
  11. 11.
    Kaiman J, Buchholz C, Steinmetz M et al (1995) Safety and efficacy of β-blockade in patients with chronic congestive heart failure awaiting transplantation. J Heart Lung Transplant 14: 1212–1217Google Scholar
  12. 12.
    Waagstein F, Bristow MR, Swedberg K et al (1993) Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy: Metoprolol in Dilated Cardiomyopathy Trial Study Group. Lancet 342: 1441–1446PubMedCrossRefGoogle Scholar
  13. 13.
    Doval HC, Nul DR, Granceli HO et al for Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA) (1994) Randomized trial of low-dose amiodarone in severe congestive heart failure. Lancet 344: 493–498PubMedCrossRefGoogle Scholar
  14. 14.
    Nul DR, Doval HC, Grancelli HO et al on behalf of the GESICA-GEMA Investigators (1997) Heart rate is a marker of amiodarone mortality reduction in severe heart failure. J Am Coll Cardiol 29: 1199–1205PubMedCrossRefGoogle Scholar
  15. 15.
    Packer M, Christopher M, O’Connor et al for the Prospective Randomized Amlodipine Survival Evaluation Study Group (PRAISE) (1996) Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 335: 1107–1114PubMedCrossRefGoogle Scholar
  16. 16.
    Pitt B, Segal R, Martinez FA et al on behalf of the ELITE Study Investigators (1997) Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, Elite). Lancet 349: 747–752PubMedCrossRefGoogle Scholar
  17. 17.
    Dunkman WB, Johnson GR, Carson PE et al (1993) Incidence of thromboembolic events in congestive heart failure. Circulation 87[Suppl VI]: VI94–VI101PubMedGoogle Scholar
  18. 18.
    Frigerio M, Gronda EG, Mangiavacchi M et al (1997) Restrictive criteria for heart transplantation candidacy maximizes survival of patients with advanced heart failure. J Heart Lung Transplant 16: 160–168PubMedGoogle Scholar
  19. 19.
    Rodeheffer RJ, Naftel DC, Stevenson LW et al and The Cardiac Transplant Research Database Group (1996) Secular trends in cardiac transplant recipient and donor management in the United States, 1990 to 1994. A Multi-Institutional Study Circulation 94: 2883–2889Google Scholar
  20. 20.
    Opasich C, Febo O, Riccardi G et al (1996) Concomitant factors of decompensation in chronic heart failure. Am J cardiol 78: 354–357PubMedCrossRefGoogle Scholar
  21. 21.
    Niebauer J, Coats AJS (1997) Treating, chronic heart failure: time to take stock. Lancet 349: 966–967PubMedCrossRefGoogle Scholar
  22. 22.
    Anker SD, Ponikowski P, Varney S et al (1997) Wasting as independent risk factor for mortality in chronic heart failure. Lancet 349: 1050–1053PubMedCrossRefGoogle Scholar
  23. 23.
    Constanzo MR, Augustine S, Bourge R et al (1995) Selection and treatment of candidates for heart transplantation. A statement for health professionals from the Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. Circulation 92: 3593–3612CrossRefGoogle Scholar
  24. 24.
    Stevenson LW, Hamilton MA, Tillisch JH et al (1991) Decreasing survival benefit from cardiac transplantation for outpatients as the waiting list lengthens. J Am Coll Cardiol 18: 919–925PubMedCrossRefGoogle Scholar
  25. 25.
    Levine TB, Levine AB, Goldberg AD et al (1996) Clinical status of patients removed from a transplant waiting list rivals that of transplant recipients at significant cost savings. Am Heart J 132: 1189–1194PubMedCrossRefGoogle Scholar
  26. 26.
    Levine TB, Levine A, Goldberg AD et al (1996) Reversal of end-stage heart failure is predicted by long-term therapeutic response rather than initial hemodynamic and neurohormonal profile. J Heart Lung Transplant 15: 297–303PubMedGoogle Scholar
  27. 27.
    Bocchi EA, Bellotti G, Moreira LF et al (1996) Mid-term results of heart transplantation, car-diomyoplasty, and medical treatment of refractory heart failure caused by idiopathic dilated cardiomyopathy. J Heart Lung Transplant 15: 636–645Google Scholar
  28. 28.
    Auler JOC, Bacal F, Bocchi EA (1996) Cardiac Transplantation or ventriculectomy? In: Gullo A (ed) Anaesthesia, pain, intensive care, and emergency medicine. Critical care medicine. Springer, pp 695–707Google Scholar
  29. 29.
    Blum A, Aravot D (1996) Heart transplantation-An update. Clin Cardiol 19: 930–938PubMedCrossRefGoogle Scholar
  30. 30.
    Torre G, Kapadia S, Short D (1996) Evolving concepts regarding selection of patients for cardiac transplantation. Chest 109: 223–232CrossRefGoogle Scholar
  31. 31.
    Report of the American College of cardiology/American Heart Association Task Force on Practice Guidelines (1995) Guidelines for the evaluation and management of heart failure. Circulation 92: 2764–2784CrossRefGoogle Scholar
  32. 32.
    Frazier OH (1995) New technologies in the treatment of severe cardiac failure: the Texas Heart Institute experience. AnnThorac Surg 59: S31–S38CrossRefGoogle Scholar
  33. 33.
    Scheid HH (1997) Mechanical support-benefits and risks. Thorac Cardiovasc Surg 45: 1–5CrossRefGoogle Scholar
  34. 34.
    Kormos RL, Murali S, Dew MA et al (1994) Chronic mechanical circulatory support rehabilitation, low morbidity, and superior survival. Ann Thorac Surg 57: 51–58PubMedCrossRefGoogle Scholar
  35. 35.
    Loissance DY, Ouillart F, Benvenutti C et al (1996) Mechanical bridge to transplantation: When is too early? When is too late. Ann Thorac Surg 61: 388–390CrossRefGoogle Scholar
  36. 36.
    Westaby S (1996) The need for artificial hearts. Heart 76: 200–206PubMedCrossRefGoogle Scholar
  37. 37.
    Tayama E, Nose Y (1996) Can we treat dilated cardiomyopathy using a left ventricular assist device? Artificial Organs 20: 197–201PubMedCrossRefGoogle Scholar
  38. 38.
    Bocchi EA, Vieira MLC, Fiorelli A et al (1994) Perfil hemodinamico e neuro-hormonal durante assistencia circulatoria com ventrículo artificial heterotópico seguida de transplante cardíaco. Arq Bras Cardiol 62: 23–27PubMedGoogle Scholar
  39. 39.
    Bocchi EA, Moreira LF, Bellotti G et al (1991) Hemodynamic study during upright isotonic exercise before and six months after dynamic cardiomyoplasty for idiopathic dilated cardiomyopathy or Chagas’ disease. Am J Cardiol 67: 213–214PubMedCrossRefGoogle Scholar
  40. 40.
    Bocchi EA, Moreira LFP, Moraes AV et al (1992) Effects of dynamic cardiomyoplasty on regional wall motion, ejection fraction, and geometry of left ventricle. Circulation 86[Suppl II]: II231–II235PubMedGoogle Scholar
  41. 41.
    Bocchi EA, Guimarães GV, Moreira LF et al (1995) Peak oxygen consumption and resting left ventricular ejection fraction after cardiomyoplasty at 6-month follow-up. Circulation 92[Suppl II]: II216–II222PubMedGoogle Scholar
  42. 42.
    Kalil-Filho R, Bocchi EA, Weiss RG et al (1994) Magnetic resonance imaging evaluation of chronic changes in latissimus dorsi cardiomyoplasty. Circulation 90[Part 2]: II102–II106PubMedGoogle Scholar
  43. 43.
    Bocchi EA, Bellotti G, Moreira LFP et al (1994) Prognostic indicators of one-year outcome after cardiomyoplasty for idiopathic dilated cardiomyopathy. Am J Cardiol 73: 604–608PubMedCrossRefGoogle Scholar
  44. 44.
    Magovern GJ, Simpaon FA (1996) Clinical cardiomyoplasty: reviewer of the ten-year United States experience. Ann Thorac Surg 61: 413–419PubMedCrossRefGoogle Scholar
  45. 45.
    Borghetti-Maio SA, Romano BW, Bocchi EA et al (1994) Quality of life after cardiomyoplasty. J Heart Transplant 13: 271–275Google Scholar
  46. 46.
    Furnary AP, Mariell J, Moreira LFP for the American Cardiomyoplasty Group (1996) Multicenter trial of dynamic cardiomyoplasty for chronic heart failure. J Am Coll Cardiol 28: 1175–1180PubMedCrossRefGoogle Scholar
  47. 47.
    Batista RJV, Santos JLV, Taheshita N et al (1996) Partial left ventriculectomy to improve left ventricular function in end-stage heart disease. J Card Surg 11: 96–97PubMedCrossRefGoogle Scholar
  48. 48.
    Bocchi EA, Moraes AV, Bacal F et al (1996) Clinical outcome after surgical remodeling of left ventricle in candidates to heart transplantation with idiopathic dilated cardiomyopathy. Short-term results. Circulation 94: I–172Google Scholar
  49. 49.
    Bellotti G, Moraes AV, Bocchi EA et al (1996) Surgical remodeling of the left ventricle in severe dilated cardiomyopathy. Short-term results on cardiac mechanics. Circulation 94: I–548Google Scholar
  50. 50.
    McCarthy PM, Starling RC, Smedira NG et al (1997) Partial left ventriculectomy with valve repair as an alternative to cardiac transplantation. J Heart Lung Transplant 16: 41Google Scholar
  51. 51.
    Bocchi EA, Moreira LF, Moraes AV et al (1994) Arrhythmias and sudden death after dynamic cardiomyoplasty. Circulation 90[Part 2]: II107–II111PubMedGoogle Scholar
  52. 52.
    Lindsay BD, Osborn JL, Schechtman KB et al (1992) Prospective detection of vulnerability to sustained ventricular tachycardia in patients awaiting cardiac transplantation. Am J Cardiol 69: 619–624PubMedCrossRefGoogle Scholar
  53. 53.
    Aguillar JC, Luna AB, Lopez FN et al on behalf of the group MUSIC (1996) Sudden death in heart failure. Rev Esp Cardiol 49: 732–740Google Scholar
  54. 54.
    Doval HC, Nul DR, Grancolli HO et al for the Gesica-GEMA Investigators (1996) Nonsustained ventricular tachycardia in severe heart failure-Independent marker of increased mortality due to sudden death. Circulation 94: 3198–3203PubMedCrossRefGoogle Scholar
  55. 55.
    Cohn JN (1996) The management of chronic heart failure. N Engl J Med 335: 490–498PubMedCrossRefGoogle Scholar
  56. 56.
    Singh SN (1997) Congestive heart failure and arrhythmias: Therapeutic modalities. J Cardiovasc Electrophysiol 8: 89–97PubMedCrossRefGoogle Scholar
  57. 57.
    Moss AJ, Hall J, Cannom DS et al for the Multicenter Automatic Defibrillator Implantation Trial Investigators (1996) Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 335: 1933–1940PubMedCrossRefGoogle Scholar
  58. 58.
    Saxon LA, Wiener I, DeLuirgio DB et al (1995) Implantable defibrillators for high-risk patients with heart failure who are awaiting cardiac transplantation. Am Heart J 130: 501–506PubMedCrossRefGoogle Scholar
  59. 59.
    Sweeney MO, Ruskin JN, Garan H et al (1995) Influence of implantable cardioverter/defibrillator on sudden death and total mortality in patients evaluated for cardiac transplantation. Circulation 92: 3273–3281PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia, Milano 1998

Authors and Affiliations

  • E. A. Bocchi
  • F. Bacal
  • J. O. Auler

There are no affiliations available

Personalised recommendations